Home » Stocks » CPHI

China Pharma Holdings, Inc. (CPHI)

Stock Price: $0.780 USD 0.006 (0.78%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 35.53M
Revenue (ttm) 10.98M
Net Income (ttm) -20.40M
Shares Out 43.58M
EPS (ttm) -0.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $0.780
Previous Close $0.774
Change ($) 0.006
Change (%) 0.78%
Day's Open 0.761
Day's Range 0.708 - 0.789
Day's Volume 451,364
52-Week Range 0.320 - 1.310

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 4 months ago

Face mask play China Pharma Holdings is trending higher today, and investors are noticing. Here is what you should know about CPHI stock.

Seeking Alpha - 11 months ago

China Pharma Holdings Inc. (CPHI) CEO Zhilin Li on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

China Pharma's (CPHI) CEO Zhilin Li on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q4 2018 Results - Earnings Call Transcript

About CPHI

China Pharma Holdings develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brai... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
CEO
Zhilin Li
Employees
228
Stock Exchange
NYSEAMERICAN
Ticker Symbol
CPHI
Full Company Profile

Financial Performance

In 2019, CPHI's revenue was $10.92 million, a decrease of -11.41% compared to the previous year's $12.33 million. Losses were -$20.70 million, 92.6% more than in 2018.

Financial Statements